Recruiting

Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy

ClinicalTrials.gov IDNCT06309290

PhaseNA

Enrollment68

SponsorUniversidad de La Frontera

AgeNo minimum reported

SexFEMALE

I'm interested View official listing

Conditions studied

Prehabilitation, Breast Cancer, Postmenopause, Resistance Training

About this study

Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.

Interventions

Other: Prehabilitation with resistance-exercise training — The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
Other: Usual care program — The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).

Primary outcomes

Change in skeletal muscle mass (measured via Computed tomography (CT) scan) (Before training (week 0), and after training (up to 20 weeks) and 4 weeks post surgery)

Eligibility information

Inclusion Criteria: * Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC * Indication for neoadjuvant chemotherapy * Candidates for curative breast surgery * Body mass index: 18.5 \<BMI \<30 kg/m2 * Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week) * Willingness to participate in the study and follow the proposed prehabilitation scheme. Exclusion Criteria: * Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others). * Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50% * Previous antineoplastic treatment * Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).

Study locations

Fundación Arturo López Pérez, Santiago, Chile
Department of Rehabilitation Sciences, Faculty of Medicine, Universidad de La Frontera. Temuco, Chile, Temuco, Chile

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.